Recombinant Newcastle disease virus as a vaccine vector
/in International Publications, Newcastle Disease Virus /von 2003-06-01 / Poult. Sci. 2003 Jun;82(6):899-906TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21Postirradiation malignant fibrous histiocytoma of the larynx: a case report
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2002-09-01 / Am J Otolaryngol 2002 Sep-Oct;23(5):293-6Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease Virus /von 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-93Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
/in International Publications, Newcastle Disease Virus /von 2002-05-01 / J. Clin. Oncol. 2002 May;20(9):2251-66Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus
/in Hyperthermia, International Publications, Newcastle Disease Virus /von 2001-12-01 / Cancer Res. 2001 Dec;61(23):8361-5Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration
/in International Publications, Newcastle Disease Virus /von 2001-10-22 / Cancer Lett. 2001 Oct;172(1):27-36Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
/in International Publications, Newcastle Disease Virus /von 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2001-05-01 / J. Neurooncol. 2001 May;53(1):39-46IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de